BMC Cancer is calling for submissions to our Collection on new advances in the treatment of blood cancers.
Hematological malignancies are a highly heterogeneous group of cancers arising in blood and lymph-forming tissues and the fifth most common cancer type in economically developed countries. Despite remarkable progress in basic, translational, and clinical research, resulting in improved survival rates for most hematological malignancies, managing patients with relapsed/refractory cancers remains a huge challenge in clinical oncology. Indeed, new effective treatments focusing on removing malignant cells and minimizing side effects are of great importance. Targeted therapies or personalized medicine are now emerging as new therapeutic options. Therefore, identifying new potential therapeutic targets through identifying new driver mutations, studying the interactions between pathways that may promote tumor-cell growth or confer drug resistance, and investigating the interplay between cancer cells and the tumor microenvironment is paramount in blood cancer research. The advances in technology and computing play a big role in identifying new targets, leading to the ability to perform high-throughput assays, multiplexed imaging, and big-data sharing.
In recognition of this relevant field, BMC Cancer has launched this Collection which encourages submissions including but not limited to those addressing:
● Clonal hematopoiesis and pre-malignancies
● Biotechnological advances in cell engineering and manufacturing (iPSC-derived cell therapeutics, off-the-shelf stem cell therapies, CAR-T cell therapy)
● Genomic landscape studies and identification of new driver mutations and molecular targets
● Targeted immunotherapies
● Therapeutic advances at all stages of development, from experimental treatments in animal models to clinical trials
● Advances in bone marrow transplantation and management of therapy side effects
● New predictive biomarkers
● Advances in minimal residual disease evaluation
● Mechanisms of therapeutic resistance
Image credit: SciePro / stock.adobe.com